HAYA Therapeutics SA
Edit

HAYA Therapeutics SA

http://www.hayatx.com/
Last activity: 25.06.2025
Active
Categories: BioTechDevelopmentLearn
Pioneering next-generation therapies for fibrotic diseases. Learn more about our approach here.
Mentions
38
Total raised: $90.04M

Investors 2

Funding Rounds 3

DateSeriesAmountInvestors
08.05.2025Series A$65M-
09.02.2022Seed$5M-
20.05.2021Seed$20.04M-

Mentions in press and media 38

DateTitleDescription
25.06.20252025 WEF Technology Pioneers highlight two Swiss Startups Celebrating its 25th anniversary this year, the World Economic Forum’s Technology Pioneers programme community helps early-stage start-ups with technologies that can positively shape our future to grow. Since 2000, the initiative has recog...
03.06.2025Un jubilé synonyme de renaissance Le 25e anniversaire du service de valorisation de la recherche de la CHUV et de l'UNIL a été célébré au Biopôle, dans le nouvel auditorium SE-C, en présence d'une communauté enthousiaste de chercheurs, de start-ups et de représentants d'en...
08.05.2025HAYA Therapeutics: Pioneering the Future of RNA-Guided TherapiesIn the world of biotechnology, innovation is the lifeblood. HAYA Therapeutics has just secured a hefty $65 million in Series A funding, a financial boost that could change the landscape of chronic and age-related disease treatment. This fun...
08.05.2025HAYA Therapeutics Raises $65M in Series A FundingHaya Therapeutics, a Lausanne, Switzerland- and San Diego, CA-based biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics that reprogram disease-driving cell states for rare, common, chronic and age-...
08.05.2025HAYA Therapeutics: $65 Million Series A Closed To Deliver Precision RNA-Guided MedicinesHAYA Therapeutics – a biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics that reprogram disease-driving cell states for rare, common, chronic and age-related diseases – announced that the company ...
08.05.2025HAYA Therapeutics secures USD 65M to advance RNA-guided therapies for chronic and age-related diseasesProceeds from the USD 65 million round will fund clinical trials for HTX-001, HAYA Therapeutics's lead candidate for non-obstructive hypertrophic cardiomyopathy (nHCM), and support pipeline expansion into conditions such as pulmonary fibros...
08.05.2025HAYA Therapeutics banks $65 million Series A funding HAYA Therapeutics is a biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics that reprogram disease-driving cell states for rare, common, chronic and age-related diseases. The core of HAYA’s proprie...
06.05.2025The Stock Market: A Tug of War Between Optimism and UncertaintyThe stock market is a living organism. It breathes, pulses, and reacts to the world around it. As we step into this week, the atmosphere is thick with anticipation. Wall Street is poised for a lower open, a signal that the calm may be fleet...
05.05.2025Recognition for Swiss innovators across the globe Haya Therapeutics’ CEO, Samir Ounzain, has been recognized as one of the top innovators in The Medicine Maker Power List, under the “Advanced Medicine” category. Samir focuses on a new area of drug development focused on the regulatory gen...
17.03.2025Seasoned executives join Swiss startups VertX IQ has welcomed Tamara Jost as our new Chief Technology Officer, bringing a wealth of fintech expertise to drive innovation and enhance the startup’s technology capabilities. Founded in 2020, VertX IQ is a financial services and tech...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In